File Download
  Patent History
  • Application
    PC T/CN2007003005 2007-10-22
  • Publication
    WO 2008049330 2008-05-02

published patent: USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET

TitleUSE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
Priority Date2006-10-20 US 11/853404P
Inventors
Issue Date2008
Citation
WO Published patent application WO 2008049330. World Intellectual Property Organization (WIPO), PatentScope, 2008 How to Cite?
AbstractMethods and compositions for identifying and treating obesity and obesity induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.
Persistent Identifierhttp://hdl.handle.net/10722/177123
References

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:39:11Z-
dc.date.available2012-11-30T08:39:11Z-
dc.date.issued2008-
dc.identifier.citationWO Published patent application WO 2008049330. World Intellectual Property Organization (WIPO), PatentScope, 2008en_HK
dc.identifier.urihttp://hdl.handle.net/10722/177123-
dc.description.abstractMethods and compositions for identifying and treating obesity and obesity induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.en_HK
dc.relation.isreferencedbyWO 2012042061 (A1) 2012-04-05en_HK
dc.relation.isreferencedbyWO 2011156715 (A2) 2011-12-15en_HK
dc.relation.isreferencedbyWO 2011156715 (A3) 2012-05-10en_HK
dc.relation.isreferencedbyWO 2010132479 (A3) 2011-03-31en_HK
dc.relation.isreferencedbyWO 2010132479 (A2) 2010-11-18en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleUSE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGETen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorXu, Aen_HK
dc.contributor.inventorWang, Yen_HK
dc.contributor.inventorLam, KSLen_HK
patents.identifier.applicationPC T/CN2007003005en_HK
patents.description.assigneeUNIV HONG KONG [CN]; XU AIMIN [CN]; WANG YU [CN]; LAM SIULING KAREN [CN]en_HK
patents.description.countryWorld Intellectual Property Organization (WIPO)en_HK
patents.date.publication2008-05-02en_HK
dc.relation.referencesUS 2004132984 (A1) 2004-07-08en_HK
dc.relation.referencesCN 1040323 (C) 1998-10-21en_HK
dc.relation.referencesCN 1101911 (A) 1995-04-26en_HK
dc.relation.referencesCN 1302206 (A) 2001-07-04en_HK
dc.relation.referencesUS 5702902 (A) 1997-12-30en_HK
dc.relation.referencesUS 2004002112 (A1) 2004-01-01en_HK
patents.date.application2007-10-22en_HK
patents.date.priority2006-10-20 US 11/853404Pen_HK
patents.description.ccWOen_HK
patents.identifier.publicationWO 2008049330en_HK
patents.relation.familyUS 2008095782 (A1) 2008-04-24en_HK
patents.relation.familyUS 7645616 (B2) 2010-01-12en_HK
patents.relation.familyUS 2010310578 (A1) 2010-12-09en_HK
patents.relation.familyWO 2008049330 (A1) 2008-05-02en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats